Pular para o conteúdo principal
Ranking Invest

ANNX - Annexon, Inc.

Segmento: HealthcareAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Análise Ranking Invest

Valuation estimado
-18,60%
-$ 386.69 Mi
Valor de Mercado
$ 743.15 Mi
Desconto (AV)-292.2%
IVR
-0.52A companhia vale -0,52 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.80O valuation alternativo equivale a -80% do valor de mercado da companhia.
MLL
-0.80O lucro líquido dos controladores em 16 trimestres equivale a -80% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 186.06 Mi

Dívida Líquida

-$ 199.27 Mi

L4T

-$ 202.67 Mi

Indicadores Básicos

ROE

-108.93%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.15

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

G-9.03

Margem

D0.00

Índices de Endividamento

DIV/PAT

-1.07

DIV/L4T

0.98

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.